EUCTR2005-002825-29-FRActive, not recruitingPhase 1
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. - BOS
European Organisation for Research and Treatment of Cancer0 sites0 target enrollmentStarted: October 4, 2006Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •-male or female patients with potentially resectable liver metastases from CRC
- •-patients with metachronous or synchronous metastases who have undergone comlete resection (R0) of the primary tumour at least 4 weeks before randomization into the study
- •-no evidence of extra-hepatic disease
- •-patients can be entered in the study irrespective of the EGFR-expression status of their CRC
- •-WHO performance status: 0,1
- •-age: 18 to 80 years
- •-no previous chemotherapy for metastatic disease
- •-any previous adjuvant chemotherapy for primary cancer is allowed, except for patients who ended an oxaliplatin containing adjuvant treatment less than 12 months ago, and except for patients with persisting neuropathy
- •-no previous exposure to EGFR- or VEGF/VEGFR-targeting therapy
- •-absolute neutrophil count > 1.5 x 109 /L, platelets > 100 x 109/L, hemoglobin > 9 g/dL, and white blood cell count (WBC) > 3 x 109 /L
- •-serum creatinine less than 1.5 times the upper limit of normal (ULN); no significant proteinuria (>500 mg/24 hours urine collection)
- •-written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization
- •- peripheral neuropathy and serious nonhealing wound, ulcer, or bone fracture
- •- clinically significant cardiovascular disease
- •- pregnancy or breast feeding. Adequate contraception is required for both male and female patienst if the risk of conception exists. Methods of adequate contraception are: condon use with spermicide, hormonal contraception, intra-uterine device
- •- participation in another clinical study within the 30 days before randomization
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. - BOSresectable liver metastases of colorectal cancerEUCTR2005-002825-29-DEEuropean Organisation for Research and Treatment of Cancer100
Active, not recruiting
Not Applicable
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer.EUCTR2005-002825-29-ATEuropean Organisation for Research and Treatment of Cancer100
Active, not recruiting
Not Applicable
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. - BOSresectable liver metastases of colorectal cancerEUCTR2005-002825-29-SEEuropean Organisation for Research and Treatment of Cancer100
Active, not recruiting
Not Applicable
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer. - BOSresectable liver metastases of colorectal cancerEUCTR2005-002825-29-BEEuropean Organisation for Research and Treatment of Cancer100
Active, not recruiting
Phase 1
Randomized phase II trial evaluating the feasibility and tolerance of the combination of FOLFOX with cetuximab and the combination of FOLFOX with cetuximab and bevacizumab as perioperative treatment in patients with resectable liver metastases from colorectal cancer.resectable liver metastases of colorectal cancerMedDRA version: 8.1 Level: LLT Classification code 10052358 Term: Colorectal cancer metastaticEUCTR2005-002825-29-GBEuropean Organisation for Research and Treatment of Cancer